Suppression of murine melanoma growth by a vaccine of attenuated Salmonella carrying heat shock protein 70 and Herpes simplex virus-thymidine kinase genes

Oncology Reports

Volumn 27, Issue 3, 2012, Pages 798-806

  Zeng, Shuguang ^a   Zhang, Jincai ^a   Zhang, Jiren ^a   Liu, Qicai ^b   Wang, Suwen ^a   Wu, Shiqing ^a   Peng, Ximao ^a   Shao, Jing ^c   Huang, Wenge ^c  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Cancer; Heat shock protein 70; Herpes simplex virus thymidine kinase; Recombinant DNA; Salmonella; Vaccine

Indexed keywords

BACTERIAL VECTOR; DNA VACCINE; GAMMA INTERFERON; GANCICLOVIR; HEAT SHOCK PROTEIN 70; MYCOBACTERIUM TUBERCULOSIS HEAT SHOCK PROTEIN 70 THYMIDINE KINASE VACCINE; THYMIDINE KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CANCER GENE THERAPY; CANCER INHIBITION; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOFLUORESCENCE TEST; IN VITRO GENE TRANSFER; MELANOMA B16; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SALMONELLA TYPHIMURIUM; TUMOR CELL DESTRUCTION;

ANIMALS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; HSP70 HEAT-SHOCK PROTEINS; INTERFERON-GAMMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MYCOBACTERIUM TUBERCULOSIS; PLASMIDS; SALMONELLA; SALMONELLA INFECTIONS; SALMONELLA VACCINES; SIMPLEXVIRUS; THYMIDINE KINASE; TRANSFECTION; VACCINES, ATTENUATED; VIRAL PROTEINS;

EID: 84863035832     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1556     Document Type: Article

References (29)

1. Srivastava IK and Liu MA: Gene vaccines. Ann Intern Med 138: 550-559, 2003.
2. Triozzi PL, Aldrich W, Allen KO, Carlisle RR, LoBuglio AF and Conry RM: Phase I study of a plasmid DNA vaccine encoding MART-1 in patients with resected melanoma at risk for relapse. J Immunother 28: 382-388, 2005. (Pubitemid 40962332)
3. Young JG, Green NK, Mautner V, Searle PF, Young LS and James ND: Combining gene and immunotherapy for prostate cancer. Prostate Cancer Prostatic Dis 11: 187-193, 2008. (Pubitemid 351676609)
4. Somoto H, Ohtsuru A, Braiden V, et al: Heat-directed suicide gene therapy mediated by heat shock protein promoter for gastric cancer. Oncol Rep 15: 629-635, 2006.
5. Lee YJ, Lee H and Borrelli MJ: Gene transfer into human prostate adenocarcinoma cells with an adenoviral vector: hyperthermia enhances a double suicide gene expression, cytotoxicity and radiotoxicity. Cancer Gene Ther 9: 267-274, 2002. (Pubitemid 34205501)
6. Parry JJ, Sharma V, Andrews R, Moros EG, Piwnica-Worms D and Rogers BE: PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts. Cancer Gene Ther 16: 161-170, 2009.
7. Ren W, Strube R, Zhang X, Chen SY and Huang XF: Potent tumor-specific immunity induced by an in vivo heat shock protein-suicide gene-based tumor vaccine. Cancer Res 64: 6645-6651, 2004. (Pubitemid 39297925)
8. Wendling U, Paul L, van der Zee R, Prakken B, Singh M and van Eden W: A conserved mycobacterial heat shock protein (hsp) 70 sequence prevents adjuvant arthritis upon nasal administration and induces IL-10-producing T cells that cross-react with the mammalian self-hsp70 homologue. J Immunol 164: 2711-2717, 2000. (Pubitemid 30115504)
9. Wells AD and Malkovsky M: Heat shock proteins, tumor immunogenicity and antigen presentation: an integrated view. Immunol Today 21: 129-132, 2000. (Pubitemid 30122702)
10. Gaston JS: Heat shock proteins as potential targets in the therapy of inflammatory arthritis. Biotherapy 10: 197-203, 1998.
11. Pawelek JM, Low KB and Bermudes D: Bacteria as tumour-targeting vectors. Lancet Oncol 4: 548-556, 2003. (Pubitemid 38351712)
12. Cunningham C and Nemunaitis J: A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Hum Gene Ther 12: 1594-1596, 2001.
13. Agorio C, Schreiber F, Sheppard M, et al: Live attenuated Salmonella as a vector for oral cytokine gene therapy in melanoma. J Gene Med 9: 416-423, 2007. (Pubitemid 46796587)
14. Pawelek JM, Low KB and Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res 57: 4537-4544, 1997. (Pubitemid 27441058)
15. Hoiseth SK and Stocker BA: Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 291: 238-239, 1981. (Pubitemid 11081517)
16. Zhao M, Yang M, Ma H, et al: Targeted therapy with a Salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res 66: 7647-7652, 2006. (Pubitemid 44289222)
17. Avogadri F, Martinoli C, Petrovska L, et al: Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res 65: 3920-3927, 2005. (Pubitemid 40616374)
18. Sizemore DR, Branstrom AA and Sadoff JC: Attenuated bacteria as a DNA delivery vehicle for DNA-mediated immunization. Vaccine 15: 804-807, 1997. (Pubitemid 27287961)
19. Figueroa-Bossi N, Uzzau S, Maloriol D and Bossi L: Variable assortment of prophages provides a transferable repertoire of pathogenic determinants in Salmonella. Mol Microbiol 39: 260-271, 2001. (Pubitemid 32113500)
20. Curtiss R III: Bacterial infectious disease control by vaccine development. J Clin Invest 110: 1061-1066, 2002.
21. Theys J, Barbé S, Landuyt W, et al: Tumor-specific gene delivery using genetically engineered bacteria. Curr Gene Ther 3: 207-221, 2003.
22. Kitamura S, Kondo S, Shinomura Y, et al: Expression of hepatocyte growth factor and c-met in ulcerative colitis. Inflamm Res 49: 320-324, 2000.
23. Platt J, Sodi S, Kelley M, et al: Antitumour effects of genetically engineered Salmonella in combination with radiation. Eur J Cancer 36: 2397-2402, 2000.
24. Darji A, Guzmán CA, Gerstel B, et al: Oral somatic transgene vaccination using attenuated S. typhimurium. Cell 91: 765-775, 1997. (Pubitemid 28007733)
25. Shilling DA, Smith MJ, Tyther R, et al: Salmonella typhimurium stimulation combined with tumour-derived heat shock proteins induces potent dendritic cell anti-tumour responses in a murine model. Clin Exp Immunol 149: 109-116, 2007. (Pubitemid 46897103)
26. Vassaux G, Nitcheu J, Jezzard S and Lemoine NR: Bacterial gene therapy strategies. J Pathol 208: 290-298, 2006. (Pubitemid 43126121)
27. Hummel S, Apte RN, Qimron U, Vitacolonna M, Porgador A and Zöller M: Tumor vaccination by Salmonella typhimurium after transformation with a eukaryotic expression vector in mice: impact of a Salmonella typhimurium gene interfering with MHC class I presentation. J Immunother 28: 467-479, 2005. (Pubitemid 41232568)
28. Smyth MJ, Hayakawa Y, Takeda K and Yagita H: New aspects of natural-killer-cell surveillance and therapy of cancer. Nat Rev Cancer 2: 850-861, 2002. (Pubitemid 37328903)
29. Roger T, David J, Glauser MP and Calandra T: MIF regulates innate immune responses through modulation of Toll-like receptor 4. Nature 414: 920-924, 2001. (Pubitemid 34024744)